Clinical Trials Logo

Carcinoma, Small Cell Lung clinical trials

View clinical trials related to Carcinoma, Small Cell Lung.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05557708 Not yet recruiting - Clinical trials for Carcinoma, Small-Cell Lung

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT03871205 Not yet recruiting - Clinical trials for Carcinoma, Non-Small Cell Lung

Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

Start date: April 1, 2019
Phase: Phase 1
Study type: Interventional

Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are highly suitable for the development of cancer vaccines. The study aims to evaluate the safety and efficacy of neoantigen-loaded dendritic cell (DC) vaccines for refractory lung cancer.